SPY319.34+7.98 2.56%
DIA271.54+8.21 3.12%
IXIC9,814.08+198.27 2.06%

Epizyme To Present Data From Tazemetostat At ASCO May 29

Epizyme, Inc. (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today announced that multiple abstracts have been accepted for poster presentations

Benzinga · 05/13/2020 21:40

Epizyme, Inc. (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today announced that multiple abstracts have been accepted for poster presentations during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, being held May 29-31, 2020.

“We are pleased to participate in ASCO’s virtual program, reporting the pooled data from the two Phase 2 study cohorts of tazemetostat for epithelioid sarcoma, which supported the approval of TAZVERIK™ in January, as well as a presentation of the trial design for our ongoing confirmatory trial in epithelioid sarcoma,” said Dr. Shefali Agarwal. “We will also report the final data from our study of tazemetostat as a monotherapy for mesothelioma, originally presented at ASCO 2018, and early data from the Phase 1b portion of our trial of tazemetostat in pediatric patients with INI1-negative tumors. As we look ahead, 2020 is an important year for the commercialization of TAZVERIK, as well as advancing our tazemetostat clinical program in multiple additional cancer indications and combinations.”

All posters will be available online on May 29, 2020, and details of the abstracts are as follows:

Title: Efficacy, safety, and immune priming effect of tazemetostat in patients with epithelioid sarcoma
Authors: Mrinal M. Gounder, Silvia Stacchiotti, Patrick Schoffski, Gregory M. Cote, Victor M. Villalobos, Thierry M. Jahan, Tom Wei-Wu Chen, Ravin Ratan, Abha A. Gupta, Palma Dileo, Mark Agulnik, Antoine Italiano, Steven Attia, Olivier Mir, Joseph G. Pressey, Laura Sierra, Trupti Lingaraj, Jay Yang, Shefali Agarwal, Robin L. Jones
Abstract: 11564
Poster: 452

Title: A phase Ib/III randomized, double-blind, placebo-controlled study of tazemetostat plus doxorubicin as frontline therapy for patients with advanced epithelioid sarcoma
Authors: Shiraj Sen, Meredith A. McKean, Laura Sierra, Jessica Ainscough, Jay Yang, Anthony Hamlett, Tom Zimmerman, Melinda Merchant, Sant P. Chawla
Abstract: TPS11573
Poster: 461

Title: Phase I study of tazemetostat, an enhancer of zeste homolog-2 inhibitor, in pediatric patients with relapsed/refractory integrase interactor 1-negative tumors
Authors: Susan N. Chi, Franck Bourdeaut, Theodore W. Laetsch, Maryam Fouladi, Margaret E. Macy, Guy W. Makin, Neerav N. Shukla, Cynthia Wetmore, Ashley S. Margol, Michela Casanova, Lindsay B. Kilburn, Joanna Yi, Darren R. Hargrave, Geoffrey B. McCowage, Navin R. Pinto, David Ebb, Giles W. Robinson, Laura Sierra, Melinda Merchant, Karsten Nysom
Abstract: 10525
Poster: 412

Title: Safety and efficacy of tazemetostat, an enhancer of zeste-homolog 2 inhibitor, in patients with relapsed or refractory malignant mesothelioma
Authors: Marjorie G. Zauderer, Peter W. Szlosarek, Sylvestre Le Moulec, Sanjay Popat, Paul Taylor, David Planchard, Arnaud Scherpereel, Thierry M. Jahan, Marianna Koczywas, Martin Forster, Robert B. Cameron, Tobias Peikert, Evren K. Argon, Neil Michaud, Jay Yang, Vikram Kansra, Dean A. Fennell
Abstract: 9058
Poster: 251